Intellipharmaceutics
30 Worcester Road
Toronto
Ontario
M9W 5X2
Canada
Tel: 416-798-3001
Fax: 416-798-3007
Website: http://www.intellipharmaceutics.com/
157 articles with Intellipharmaceutics
-
Intellipharmaceutics Announces Patent Litigation By Purdue Pharma L.P. Against Its Rexista Abuse-Deterrent Extended-Release Oxycodone
4/10/2017
-
IntelliPharmaCeutics Announces TSX Trading Symbol Change To “IPCI”
3/16/2017
-
IntelliPharmaCeutics Announces FDA Approval For 500 Mg And 750 Mg Generic Glucophage XR
2/24/2017
-
IntelliPharmaCeutics Announces 2016 Year End Results
2/10/2017
-
IntelliPharmaCeutics Announces FDA Acceptance For Filing Of NDA For Rexista (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain
2/3/2017
-
IntelliPharmaCeutics Reports On Launch Of Additional Strengths Of Generic Focalin XR By Par Pharma
1/6/2017
-
IntelliPharmaCeutics Announces Issuance Of U.S. And Canadian Patents Covering Aspects Of Its PODRAS Overdose Technology
12/21/2016
-
IntelliPharmaCeutics Submits New Drug Application For Rexista® (Oxycodone Hydrochloride Extended Release), An Abuse Deterrent Opioid Analgesic For The Treatment Of Moderate To Severe Pain
11/28/2016
-
IntelliPharmaCeutics Announces Third Quarter 2016 Results
10/14/2016
-
IntelliPharmaCeutics Signs An Exclusive License And Commercial Supply Agreement With Mallinckrodt
10/12/2016
-
IntelliPharmaCeutics Announces FDA Tentative Approval for Generic Seroquel XR
10/10/2016
-
IntelliPharmaCeutics Responds To Recent Trading Activity
9/23/2016
-
IntelliPharmaCeutics To Present At The 18th Annual Rodman & Renshaw Global Investment Conference
8/26/2016
-
IntelliPharmaCeutics Announces Second Quarter 2016 Results
7/13/2016
-
IntelliPharmaCeutics Reports Update On Rexista XR: FDA Grants Waiver Of NDA Filing Fee, And Topline Pharmacokinetics Results Indicate No Food Effect
7/5/2016
-
IntelliPharmaCeutics Announces Pricing Of $5.2 Million Public Offering Of Common Shares And Warrants
5/27/2016
-
IntelliPharmaCeutics Announces FDA Approval For 500 Mg And 750 Mg Generic Keppra XR®
2/25/2016
-
IntelliPharmaCeutics To Present At The Biotech Showcase
12/22/2015
-
IntelliPharmaCeutics To Present At The LD Micro Main Event
11/25/2015
-
IntelliPharmaCeutics To Present At The Microcap Conference
10/27/2015